GlassScriptPhysician profile
Min J Ku
NPI 1740281955
$4,716.53
in general payments reported to CMS, 2019-2025
29 companies · $1,310 in 2025
The $1,310 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $121 · 2021: $79.17 · 2022: $573 · 2023: $1,073 · 2024: $980 · 2025: $1,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,210 · Education: $110 · Consulting Fee: $41.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,210.17 |
| Education | $110.27 |
| Consulting Fee | $41.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $794.74 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $634.60 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Pfizer INC. | $401.65 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $322.05 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $257.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.71 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Csl Behring | $240.40 | 2020-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $236.40 | 2022-2025 | Tezspire |
| Genzyme Corporation | $188.08 | 2023-2025 | |
| Alk-Abello, INC | $165.63 | 2019 | |
| Genentech USA, INC. | $162.60 | 2019-2025 | Xolair |
| Abbvie INC. | $145.11 | 2022-2023 | |
| Grifols USA, LLC | $144.43 | 2022-2025 | Xembify, Gamunex-C |
| Optinose US, INC. | $125.66 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $109.14 | 2022-2025 | Orladeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $107.40 | 2019-2024 | Auvi-Q |
| Ars Pharmaceuticals Operations, INC. | $58.17 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.32 | 2020-2023 | Spiriva Respimat |
| Covis Pharma Gmbh | $51.46 | 2022-2023 | |
| Octapharma USA, INC. | $47.04 | 2019 | |
| Blueprint Medicines Corporation | $46.82 | 2023-2025 | Ayvakit |
| Adma Biomanufacturing LLC | $41.49 | 2025 | |
| Bio Products Laboratory USA, INC. | $33.79 | 2019-2023 | Coagadex, Gammaplex |
| Teva Pharmaceuticals USA, INC. | $28.63 | 2022-2023 | Airduo Digihaler |
| Ionis Pharmaceuticals, INC. | $17.10 | 2025 | Dawnzera |
| Cycle Pharmaceuticals INC | $15.63 | 2024 | Sajazir |
| Hikma Pharmaceuticals USA | $14.67 | 2025 | Ryaltris |
| Shire North American Group INC | $13.82 | 2019 | |
| Galderma Laboratories, L.P. | $13.54 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Ku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.